Last reviewed: 20 Dec 2020
Last updated: 24 Oct 2019



History and exam

Key diagnostic factors

  • presence of risk factors
  • abdominal distension
  • jaundice and pruritus
  • blood in vomit (haematemesis) and black stool (melaena)
  • hand and nail features (e.g., leukonychia, palmar erythema, spider naevi)
  • facial features (e.g., telangiectasia, spider naevi, jaundiced sclera)
  • abdominal features (e.g., collateral circulation, hepatosplenomegaly, distension)
  • altered mental status

Other diagnostic factors

  • constitutional symptoms
  • lower extremity swelling
  • hepatic fetor
  • muscle wasting
  • peripheral oedema
  • recurrent infections
  • decreased libido
  • chest wall features (e.g., gynaecomastia)
  • dyspnoea
  • chest pain
  • syncope

Risk factors

  • alcohol misuse
  • intravenous drug use
  • unprotected intercourse
  • obesity
  • country of birth
  • blood transfusion
  • tattooing

Diagnostic investigations

1st investigations to order

  • liver function tests
  • gamma-glutamyl transferase (GGT)
  • serum albumin
  • serum sodium
  • prothrombin time
  • platelet count
  • antibodies to hepatitis C virus
  • hepatitis B surface antigen
More 1st investigations to order

Investigations to consider

  • total iron, total iron binding capacity (TIBC), transferrin saturation, and ferritin
  • antinuclear antibody
  • antismooth muscle antibody
  • antimitochondrial antibody
  • serum ceruloplasmin
  • plasma alpha-1 antitrypsin
  • serum protein electrophoresis
  • abdominal ultrasound
  • abdominal CT
  • abdominal MRI
  • upper gastrointestinal endoscopy
  • liver biopsy
  • non-invasive tests of liver elasticity
More investigations to consider

Treatment algorithm


Clinical Research Fellow

Barts Liver Centre

Barts and the London School of Medicine and Dentistry




GED declares that she has no competing interests.

Reader and Honorary Consultant in Hepatology

Barts Liver Centre

Barts and the London School of Medicine and Dentistry




PTFK acts as an advisor for Gilead Sciences, Janssen, and Immunocore. PTFK has received grant funding from Gilead Sciences. These roles are unrelated to the current article.

Dr Grace E. Dolman and Dr Patrick T. F. Kennedy would like to gratefully acknowledge Dr Keith D. Lindor and Dr Flavia Mendes, previous contributors to this topic.


KDL is an unpaid advisor for Intercept Pharmaceuticals and Shire Pharmaceuticals. FM declares that she has no competing interests.

Peer reviewersVIEW ALL

Assistant Professor of Medicine

University of Chicago

Center for Liver Disease




NR declares that she has no competing interests.

Clinical Assistant Professor

Division of Gastroenterology Hepatology and Nutrition

University of Florida




CL declares that she has no competing interests.

Consultant Physician

Hon Professor in Medicine

Associate Medical Director NHSBT

Queen Elizabeth Hospital




JN declares that he has no competing interests.

Use of this content is subject to our disclaimer